Tuesday, February 20, 2024 8:40:37 AM
PR Newswire
Tue, Feb 20, 2024, 8:30 AM EST
In This Article: NRXP
NRXPW +52.04%
HOPE shares currently owned by NRXP with planned share dividend to existing NRXP shareholders
HOPE has now completed initial manufacture of Ketamine for IV infusion and plans to file FDA New Drug Application for treatment of acute suicidality upon demonstration of 2-year shelf stability (expected Q2 2024)
HOPE plans to file patient-level data from two well-controlled clinical trials comparing ketamine to placebo in patients with acute suicidality and depression, which demonstrated a statistically significant benefit (P<.001)
HOPE plans to initiate a 506(c) pre-IPO offering of pre-IPO shares for qualified investors that is structured to potentially yield both capital appreciation and a royalty on sales of ketamine
RADNOR, Pa., Feb. 20, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx Pharmaceuticals, will present a corporate overview at the BIO CEO & Investor Conference, which is scheduled to take place February 26-27, 2024, at the Marriott Marquis in New York City. Presenting with him will be Matthew Duffy, the newly-appointed co-CEO of HOPE Therapeutics.
Concurrent with the presentation, NRx plans to file a proxy statement, subject to board approval, for Nasdaq:NRXP shareholders outlining the share structure and seeking a shareholder advisory vote to support the planned share dividend for HOPE Therapeutics. The Company has received consistent advice from public shareholders that the planned share dividend and royalty coupon be distributed only to shareholders and warrant-holders who execute a covenant not to participate in short sales of the Company's stock.
"Subsequent to our initial announcement of HOPE Therapeutics in December 2023, we have focused on establishing HOPE's basic corporate and board structure, securing our manufacturing partnerships and manufacturing initial productions batches of ketamine, establishing nationwide distribution, pharmacovigilance, and medical liaison partnerships, and initiating plans to pair ketamine therapy with a novel digital therapeutic that has potential to reinforce the effect of NMDA-targeted drug therapy in reducing suicidal ideation and depression," said Dr. Javitt. "We thank our investors for their support and look forward to updating the public on our progress towards building a lifesaving therapy."
Presentation Date: Monday, February 26th, 2024
Time: 2:30 PM ET
Location: The Royale Room, Marriott Marquis, New York City
Registration: https://bcic.bio.org/registration
SIMULCAST: BIZTV
Information will be available on the NRx website at https://ir.nrxpharma.com/events prior to the conference.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a wholly-owned subsidiary of NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-to-launch-hope-therapeutics-inc-at-the-bio-ceo--investor-conference-2024-302065827.html
SOURCE NRx Pharmaceuticals
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
Recent NRXP News
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression • PR Newswire (US) • 04/30/2024 12:30:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement • PR Newswire (US) • 04/18/2024 12:32:00 PM
- NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock • PR Newswire (US) • 04/18/2024 12:30:00 PM
- NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock • PR Newswire (US) • 04/17/2024 08:45:00 PM
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections • PR Newswire (US) • 04/17/2024 12:30:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine) • PR Newswire (US) • 04/15/2024 12:30:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression • PR Newswire (US) • 04/08/2024 12:30:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • PR Newswire (US) • 04/01/2024 12:28:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights • PR Newswire (US) • 03/28/2024 12:03:00 PM
- NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing • PR Newswire (US) • 03/28/2024 12:00:00 PM
- NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 • PR Newswire (US) • 03/26/2024 08:03:00 PM
- NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK • PR Newswire (US) • 03/25/2024 12:30:00 PM
- NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024 • PR Newswire (US) • 03/21/2024 08:02:00 PM
- NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders • PR Newswire (US) • 03/21/2024 05:57:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales • PR Newswire (US) • 03/12/2024 11:49:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/11/2024 09:16:06 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine) • PR Newswire (US) • 03/11/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:08:01 PM
- NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression • PR Newswire (US) • 03/04/2024 01:30:00 PM
- NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per Share • PR Newswire (US) • 03/01/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 10:09:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/28/2024 03:40:51 PM
- /C O R R E C T I O N -- NRx Pharmaceuticals, Inc./ • PR Newswire (US) • 02/27/2024 03:49:00 PM
- NRx Pharmaceuticals, Inc. Announces Pricing of $1.5 Million Underwritten Public Offering of Common Stock Together with investor Commitment for Additional $1 million • PR Newswire (US) • 02/27/2024 01:54:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/26/2024 10:15:44 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM